<DOC>
	<DOCNO>NCT00134355</DOCNO>
	<brief_summary>The purpose study evaluate PTK787/ZK 222584 , drug block new blood vessel growth , treatment patient non-metastatic androgen independent prostate cancer . This study ass safety tolerability PTK787/ZK 222584 , evaluate serum vascular endothelial growth factor ( VEGF ) level .</brief_summary>
	<brief_title>Study PTK787 Treatment Patients With Non-Metastatic Androgen Independent Prostate Cancer</brief_title>
	<detailed_description>This open-label , phase II trial PTK787/ZK 222584 . Patients receive 750 mg daily one week , 1000 mg daily second week , 1250 mg per day thereafter . Response Assessment : In absence toxicity clinical progression , patient remain study PSA ( Prostate-specific Antigen ) double pretreatment baseline .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologic cytologic diagnosis prostate cancer No evidence metastatic disease PSAonly progression despite androgen depravation therapy antiandrogen withdrawal Patients must maintain castrate level testosterone ( &lt; 50ng/mL ) continue LHRH ( Luteinizing Hormonereleasing Hormone ) analog therapy . ECOG ( Eastern Cooperative Oncology Group ) performance status 02 ( A measure quality life 0 represent asymptomatic 5 represent death ) No prior antiVEGF therapy allow No investigational commercial agent therapy LHRH agonists/antagonists may administer concurrently intent treat patient 's malignancy Age great equal 18 year Life expectancy great 6 month Normal organ marrow function obtain within 14 day prior registration Must use adequate contraception prior study entry duration study participation . Patients may continue daily multivitamin , herbal alternative food supplement must discontinue registration . Patients must stable dos bisphosphonates start less 6 week prior protocol therapy . Uncontrolled incurrent illness Patients `` currently active '' second malignancy eligible . Major surgery less equal 4 week prior randomization Prior chemotherapy less equal 3 week prior registration Prior biologic immunotherapy less equal 2 week prior registration Prior investigational drug kind le equal 4 week prior registration Patients full field radiotherapy less equal 4 week limited field radiotherapy equal le 2 week prior registration . Patients must nonsteroidal antiandrogen blockade . Patients must evidence disease bone scan compute tomography ( CT ) scan abdomen/pelvis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>antiangiogenesis therapy</keyword>
	<keyword>vatalanib</keyword>
</DOC>